Enliven (ELVN) Therapeutics announced that it has commenced an underwritten public offering of $200M of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven’s common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. Jefferies, Goldman Sachs & Co., TD Cowen and Mizuho are acting as joint book-running managers for the proposed offering. LifeSci Capital is acting as lead manager for the proposed offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven announces updated data from ELVN-001 trial
- Enliven Therapeutics’ ELVN-001: Promising CML Treatment with Strong Safety Profile and Upcoming Phase 1b Trial Insights
- Enliven Therapeutics: Buy Rating Backed by Promising ELVN-001 Developments in CML Treatment
- Promising Potential of Enliven Therapeutics’ ELVN-001 Drives Buy Rating
- Enliven Therapeutics’ ELVN-001: Promising Efficacy and Safety in Late Line CML Market